Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist

10.1016/0304-3959(88)90209-6

10.1016/S0006-8993(99)01393-1

10.1016/S0014-2999(02)01833-2

10.1016/0304-3959(92)90133-V

Calo G Guerrini R (2013) Medicinal chemistry, pharmacology, and biological actions of peptide ligands selective for the nociceptin/orphanin FQ receptor, in Research and Development of Opioid-Related Ligands ( Ko MC Husbands SM , eds) pp 275–325, American Chemical Society, Washington, DC.

10.1016/0160-5402(91)90063-B

10.1111/j.1398-9995.1993.tb00721.x

10.1111/j.1529-8027.2006.0093.x

10.1016/0006-2952(73)90196-2

10.2174/138945007779315605

10.1016/S1056-8719(98)00021-5

10.2165/00126839-200708010-00005

10.1016/S0014-2999(00)00590-2

10.1016/j.pain.2004.03.037

Cox BM, Borsodi A, Caló G, Chavkin C, Christie MJ, Civelli O, Devi LA, Evans C, Henderson G, Höllt V et al.(2009) Opioid receptors: Introduction. Last modified on 13/10/2009. IUPHAR database (IUPHAR-DB). Available from: http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=50. Accessed January 24, 2014.

10.1124/jpet.112.194308

D'Amour, 1941, A method for determining loss of pain sensation, J Pharmacol Exp Ther, 72, 74

Dunham, 1957, A note on a simple apparatus for detecting neurological deficits in rats and mice, J Am Pharm Assoc, 46, 208, 10.1002/jps.3030460322

10.1007/s002100000266

10.1073/pnas.090514397

10.1016/j.neulet.2013.03.026

10.1016/S0014-2999(99)00112-0

10.1016/0304-3959(92)90041-9

10.1038/npp.2009.33

10.1016/j.pain.2005.05.035

10.2165/11630080-000000000-00000

10.1038/nrd2572

Linz K, Christoph T, Schiene K, Koch T, and Englberger W (2013). GRT-TA2210, a selective NOP receptor agonist, is active in mouse models of inflammatory and neuropathic pain, in EFIC–8th “Pain in Europe” Congress; 2013 October 9-12; Florence, Italy. Abstract 599. Available from: http://www2.kenes.com/efic2013/scientific/Documents/FinalAbstractbookVersion5.pdf.

Litchfield, 1949, A simplified method of evaluating dose-effect experiments, J Pharmacol Exp Ther, 96, 99

10.1038/sj.bjp.0704279

10.1016/S0304-3959(01)00437-7

10.1038/377532a0

10.1111/j.1476-5381.2012.02115.x

10.1002/(SICI)1096-9861(19980928)399:3<373::AID-CNE6>3.0.CO;2-Y

10.1111/j.1476-5381.2011.01335.x

10.1016/j.pain.2005.03.012

10.1016/0304-3940(95)12026-Z

10.1016/S0014-2999(00)00520-3

10.1007/s00213-010-2012-7

Randall, 1957, A method for measurement of analgesic activity on inflamed tissue, Arch Int Pharmacodyn Ther, 111, 409

10.1124/jpet.103.060582

Raynor, 1994, Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors, Mol Pharmacol, 45, 330

10.1126/science.270.5237.792

10.1016/j.ejphar.2007.10.031

10.1037/a0013628

10.1016/j.ejphar.2010.07.036

10.1124/jpet.111.181263

Schröder W Lambert D Ko MC Koch T (2014) Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol DOI: 10.1111/bph.12744.

10.1016/j.neuropharm.2005.04.008

Sukhtankar D Ko MC (2013) Pharmacological investigation of NOP-related ligands as analgesics without abuse liability, in Research and Development of Opioid-Related Ligands ( Ko MC Husbands SM , eds) pp 393–416, American Chemical Society, Washington, DC.

Toll, 2013, The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders, Curr Pharm Des, 19, 7451

10.1124/jpet.107.126052

10.1358/dof.2006.031.12.1047744

10.1213/01.ANE.0000075835.73967.F3

10.1016/j.bmcl.2013.03.101

10.1016/0304-3959(83)90201-4

Zöllner, 2007, Opioids, Handbook Exp Pharmacol, 177, 31, 10.1007/978-3-540-33823-9_2